Chinese state-owned Meheco Group signed a deal in mid-March with Pfizer to be its mainland China partner for the commercialization of Paxlovid, an oral COVID-19 drug that obtained conditional approval from China’s National Medical Products Administration (NMPA) earlier this year.
In less than a week, the first batch, 20,000 doses of Paxlovid, cleared customs and was shipped to Omicron-hit regions in China.
